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Abstract 
About 75% of all breast cancers are estrogen receptor 
(ER)-positive. They generally have a more favorable 
clinical behavior, prognosis, and pattern of recurrence, 
and endocrine therapy forms the backbone of treat-
ment. Anti-estrogens (such as tamoxifen and fulves-
trant) and aromatase inhibitors (such as anastrozole, 
letrozole, and exemestane) can effectively control the 
disease and induce tumor responses in a large propor-
tion of patients. However, the majority of patients prog-
ress during endocrine therapy (acquired resistance) and 
a proportion of patients may fail to respond to initial 
therapy (de novo resistance). Endocrine resistance is 
therefore of clinical concern and there is great inter-
est in strategies that delay or circumvent it. A deeper 
knowledge of the molecular mechanisms that drive 
endocrine resistance has recently led to development 
of new strategies that have the promise to effectively 
overcome it. Many resistance mechanisms have been 
described, and the crosstalk between ER and growth 
factor receptor signaling pathways seems to represent 
one of the most relevant. Compounds that are able to 
inhibit key elements of these pathways and restore en-
docrine sensitivity have been studied and more are cur-
rently under development. The aim of this review is to 
summarize the molecular pathophysiology of endocrine 
resistance in breast cancer and its impact on current 
clinical management. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Endocrine therapy forms the backbone of 
treatment for hormone receptor (HR)-positive meta-
static breast cancer (MBC) patients. Unfortunately, re-
sistance to endocrine agents develops in the majority of 
patients. A deeper knowledge of the molecular mecha-
nisms that drive endocrine resistance has boosted the 
development of strategies designed to overcome resis-
tance to endocrine therapies. In particular, co-targeting 
of receptor tyrosine kinase and intracellular signaling 
pathways (such as the PI3K-Akt-mTOR pathway) has 
emerged as a particularly promising strategy. We pre-
dict that the development of new drugs with a strong 
underlying biological rationale will quickly result in more 
personalized treatment of patients with HR-positive 
MBC and further improve outcomes.
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INTRODUCTION
Breast cancer is a leading cause of  female death world-
wide[1]. There has been a continuous decline in mortality 
over recent years as a direct result of  improvements in 
early diagnosis and increased availability of  more effec-
tive treatments[2,3]. However, despite these improvements, 
metastatic breast cancer (MBC) remains a largely incur-
able disease and new treatments need to prolong survival, 
relieve symptoms, and delay progression. 
Approximately 75% of  breast cancers express either or 
both the estrogen receptor (ER) and progesterone recep-
tor (PgR)[4]. Hormone receptor (HR)-positive and negative 
disease differ in terms of  clinical behavior, prognosis, pat-
terns of  recurrence, and aggressiveness. Patients with HR-
positive disease are likely to have more indolent disease, 
bone metastases, and late recurrences[5]. For most HR-
positive MBC patients, endocrine therapy is the preferential 
initial treatment and has a positive impact on survival.
Recently, a number of  compounds with different 
mechanisms of  action, low toxicity, and superior efficacy 
have become available for patients with HR-positive dis-
ease. Three classes of  endocrine therapies are commonly 
used to treat HR-positive MBC: selective estrogen recep-
tor modifiers (SERMs), such as tamoxifen, which directly 
bind to the ER and block its transcriptional activity; se-
lective estrogen receptor downregulators (SERDs), such 
as fulvestrant, which bind to ER and induce its degrada-
tion; and aromatase inhibitors (AIs), such as letrozole, 
anastrozole, and exemestane, which reduce the produc-
tion of  estrogen via inhibition of  the aromatase enzyme 
in peripheral tissues and within the tumor itself[6].
Unfortunately, although long-term remission is possi-
ble[7], the majority of  patients develop resistance to endo-
crine therapy[8]. Moreover, a proportion of  patients may 
have primary resistance to endocrine therapy[9]. There is 
therefore a lot of  interest in developing strategies that 
delay the onset of  endocrine resistance or circumvent ac-
quired resistance to specific drugs. 
It has recently been suggested that dysregulation of  
growth factor signaling networks and crosstalk between 
overexpressed growth factor receptors and ER play an 
important role in the endocrine-resistant phenotype[10]. 
Manipulating these networks is an attractive and poten-
tially effective strategy that aims to delay the onset, or 
eventually overcome, resistance to endocrine therapies.
The aims of  this review are to provide an overview 
of  the known mechanisms of  resistance to endocrine 
therapies and to focus on emerging strategies aimed at 
circumventing its development.
THE BIOLOGY OF THE ER
The ER is mainly a nuclear protein that modulates gene 
expression via several different pathways. A schematic of  
the biology of  ER signaling is presented in Figure 1. 
The “classical” pathway 
Estrogen is a steroidal hormone that passively diffuses 
through cell membranes to enter the cell. The “classical” 
ER pathway is initiated by estrogen-induced dimeriza-
tion of  ER and subsequent binding to specific DNA 
promoter regions, known as estrogen response elements 
(EREs), which activates transcription of  genes involved 
in promoting cellular proliferation and survival[11]. ER can 
also inhibit gene expression, particularly those involved in 
downregulation of  the cell cycle or pro-apoptotic actions. 
The transcriptional activity of  ER is regulated by a num-
ber of  co-activators (for example, members of  the p160 
family of  nuclear receptor co-activators such as SRC1 
and SRC2) that bind to ER to form large complexes[12,13]. 
In breast cancer cells, SERMs such as tamoxifen lead to 
the formation of  ER-co-repressor complexes that inhibit 
ER-dependent transcriptional activity to induce anti-
proliferative and pro-apoptotic effects. 
The “non-classical” pathway
In addition to the “classical” regulation of  gene expres-
sion, ER also regulates genes that do not harbor EREs in 
their promoter regions in a “non-classical” manner. ER 
can, in fact, interact with other proteins that are known 
to be involved in promoting gene expression, such as Fos 
and Jun[14].
Non-nuclear activities of the ER
Although the majority of  cellular ER localizes in the nu-
cleus, the ER can also localize in the cytoplasm and cell 
membrane, where it can interacts with receptor tyrosine 
kinase (RTK) growth factor receptors, such as the epider-
mal growth factor receptor (EGFR), human epidermal 
growth factor receptor-2 (HER2), or insulin-like growth 
factor-1 receptor (IGF-1R)[15]. In fact, the ER plays a key 
role in this complex intracellular signaling network and is 
strictly linked to other signaling networks[16]. A complex 
network of  bi-directional crosstalk exists at multiple lev-
els in breast cancer cells, whereby the ER pathway and 
growth factor receptor signaling pathways interact and 
potentiate one another, resulting in dysregulated prolif-
eration and growth[12].
Therefore, through direct DNA binding, co-activa-
tion, or molecular crosstalk, ER can influence tumor cell 
proliferation, survival, and malignant progression by am-
plifying the intracellular proliferative signals from RTKs 
and their downstream effectors.  
Putative mechanisms of endocrine resistance
There is strong evidence that crosstalk between growth 
factor receptor and ER pathways can mediate resistance 
to endocrine therapy. The ER exists as part of  a highly 
complex and adaptive signaling network that enables 
cancer cells to escape simple perturbations, such as those 
presented by the currently available endocrine therapies.
For example, overexpression of  members of  the 
EGFR family of  RTKs, particularly HER2, has been de-
scribed as a molecular alteration that is able to confer de 
novo resistance to anti-estrogens[12]. HER2 directly phos-
phorylates ER and its co-regulators, leading to enhanced 
Milani A et al . Overcoming endocrine resistance in metastatic breast cancer
991 December 10, 2014|Volume 5|Issue 5|WJCO|www.wjgnet.com
ligand-independent gene expression, even in the presence 
of  negative regulators such as SERMs.
There are data to suggest that patients with early 
breast cancers that overexpress HER2 obtain less benefit 
from adjuvant tamoxifen than those with HER2-negative 
tumors; furthermore, HER2 overexpression seems to be 
predictive of  a poor clinical response to tamoxifen[17,18]. 
EGFR overexpression is also predictive of  decreased 
benefit from tamoxifen[19,20] and increased risk of  disease 
progression during anti-estrogen treatment[21]. 
There is emerging evidence to suggest that long-term 
estrogen deprivation can directly induce the transcription 
of  growth factor receptors such as EGFR, HER2, and 
IGF-1R, resulting in increased activity of  their down-
stream mediators and increased cellular proliferation, the 
final result being escape from estrogen deprivation and 
ligand-autonomous growth[22-24].
Another interaction that seems to be crucial in me-
diating resistance to endocrine therapies involves the 
phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian 
target of  rapamycin (mTOR) pathway, an ubiquitous sig-
nal transduction pathway that is also interconnected with 
other RTKs, including, but not limited to, the EGFR 
family (Figure 1)[25-27]. This pathway regulates many cel-
lular functions, not least growth and proliferation, dif-
ferentiation, metabolism, migration, and survival[28], and 
it is abnormally activated in many different cancer types, 
including breast cancer, in which it has an important role 
in the development of  anti-cancer drug resistance.
Dysregulation of  this pathway is crucial in the devel-
opment of  acquired endocrine resistance. The pathway 
can become activated via increased upstream signaling 
due to activation of  RTKs, PI3K-activating mutations, 
or decreased expression of  negative regulators of  the 
pathway, such as through loss of  the tumor suppressor 
PTEN (phosphatase and tensin homolog). For example, 
several studies have established a link between upregu-
lated Akt protein expression and/or phosphorylation and 
resistance to endocrine therapy[29,30], and it is known that 
an mTOR subunit phosphorylates and activates the func-
tional domain 1 of  the ER[31,32].
In a preclinical study, deGraffenried et al[33] reported 
that breast cancer cells with high Akt activity are resistant 
to hormonal therapy but that sensitivity could be restored 
with the use of  mTOR inhibitors. Furthermore, in anoth-
er study of  ER-positive breast cancer cells, a combination 
of  mTOR inhibitor and letrozole acted synergistically to 
inhibit proliferation and trigger apoptosis[34].
However, several other mechanisms have been de-
scribed that contribute to endocrine resistance. For exam-
ple, loss of  ER expression in the evolution from primary 
to metastatic disease may contribute to the emergence 
of  estrogen resistance; data from clinical studies suggest 
that 17% of  ER-positive patients treated with adjuvant 
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Figure 1  The biology of the estrogen receptor and a schematic representation of the key mechanisms of endocrine resistance. A: Estrogen induces gene 
regulation via the “classical” pathway. Estrogen passively diffuses through cell membranes and binds to the estrogen receptor (ER), inducing receptor dimerization. 
This complex recruits co-activators (CoA) and binds regions of DNA known as estrogen response elements (EREs), promoting transcription. Aromatase inhibitors (AIs) 
negatively regulate ER activity by reducing circulating estrogen levels; B: The ER can also cooperate with other transcription factors (TFs) and regulate the transcrip-
tion of genes not harbouring EREs via the “non-classical” pathway; C: ER strictly interacts with receptor tyrosine kinases (RTKs) via their downstream effectors. ER 
can, in fact, be directly phosphorylated and activated, the final result being gene expression and a cascade of second intracellular effectors (the non-nuclear activity 
of ER); D: This strict and bi-directional crosstalk between ER and RTKs and downstream effectors is responsible for endocrine resistance; E: In breast cancer cells, 
SERMs [such as tamoxifen (Tam)] bind ER and induce the recruitment of co-repressors (CoR) that negatively regulate the activity of ER. Mutated forms of ER are able 
to enhance gene expression in spite of the presence of Tam.  
AI
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vanced breast cancer[41]. The results showed that the com-
bination of  trastuzumab and anastrozole doubled median 
progression free survival (PFS) (2.4 mo vs 4.8 mo) and 
significantly increased the overall response rate (ORR) 
(6.8% vs 20.3%), compared to anastrozole alone. Side ef-
fects were modest and manageable (maximum grade 2) 
and consisted mainly of  fatigue, vomiting, diarrhea, py-
rexia, and arthralgia. There was no statistically significant 
treatment difference in overall survival; however, this may 
have been due to 70% of  patients in the anastrozole arm 
crossing over to receive trastuzumab after progression on 
anastrozole alone.
The “Efficacy and Safety of  Letrozole Combined 
With Trastuzumab in Patients With Metastatic Breast” 
(eLEcTRA) study prematurely closed due to slow recruit-
ment. The design was the same as TanDEM but a differ-
ent AI (letrozole) was prescribed[42]. Similar to TanDEM, 
eLEcTRA showed that the addition of  trastuzumab to 
letrozole was associated with improved PFS and clinical 
benefit rate (CBR) at the cost of  a modest increase in 
overall toxicity.
The third study was “EGF30008”, a large, phase 3, 
double-blind, randomized-controlled trial conducted in 
1286 women with HR-positive breast cancer; they were 
not selected on the basis of  HER2 status (of  the 1286 
patients enrolled, 219 had HER2-positive tumors)[43,44]. 
These patients were randomized to daily oral treatment 
with letrozole (2.5 mg) plus the dual HER1-HER2 tyro-
sine kinase inhibitor lapatinib (1500 mg) vs letrozole (2.5 
mg) plus placebo. In the ER-positive/HER2-positive 
population (n = 219), the addition of  lapatinib to letro-
zole resulted in a significantly lower risk of  disease pro-
gression than with letrozole alone. The PFS was 8.2 mo 
in the combined arm vs 3.0 mo in the placebo arm. The 
ORR (28% vs 15%) and CBR (48% vs 29%) were also sig-
nificantly greater in lapatinib treated women. In contrast 
to the other two studies, the addition of  lapatinib was 
accompanied by a significant increase in the grade 1 and 
2 side effects commonly associated with dual tyrosine 
kinase inhibition, namely diarrhea (68%) and cutaneous 
rash (46%). The impact of  lapatinib plus letrozole on OS 
has not been reported. However, based upon a clinically 
meaningful increase in PFS, the United States Food and 
Drug Administration (FDA) and the European Medicines 
Agency (EMA) have approved lapatinib in combination 
with an aromatase inhibitor in this setting.
As expected, the HER2-negative patients enrolled in 
EGF30008 derived no benefit in PFS from the addition 
of  lapatinib to letrozole. Interestingly, however, in the 
sub-group of  “tamoxifen-resistant” patients (i.e., those 
relapsing during or within six months from the comple-
tion of  adjuvant tamoxifen treatment), the improvement 
in PFS was similar to HER2-positive patients, suggest-
ing that the disruption of  crosstalk between the ER and 
RTK signaling pathways might restore sensitivity to anti-
estrogens.
Recently, Finn et al[45] showed that weak ER expres-
sion is associated with worse outcomes for postmeno-
tamoxifen may convert to an ER-negative phenotype at 
the time of  relapse[35].  
Mutations in ESR1, the gene encoding ER, also seem 
to negatively affect responses to hormonal therapy[36,37]. 
Recently Toy et al[36] reported frequent mutations in 
ESR1 that affect the ligand-binding domain (LBD) 
of  ER in metastatic hormone-resistant breast cancers 
after prolonged exposure to hormonal therapy. These 
highly recurrent mutations mainly affected p.Tyr537Ser, 
p.Tyr537Asn, and p.Asp538Gly, and as a consequence 
caused an agonist conformation of  the receptor. In addi-
tion, they noted that LBD-mutant receptors have a hor-
mone-independent active state that is likely to promote 
resistance to estrogen-depriving therapies. Interestingly, 
mutant ER retains some sensitivity to drugs that directly 
target the receptor, suggesting that more potent ER an-
tagonists may be of  substantial therapeutic benefit in this 
subgroup of  individuals.
There may also be individual biological variability 
in drug metabolism that might influence responses to 
therapy. For example, about 8% of  Caucasian women fail 
to convert tamoxifen to its active metabolite, endoxifen, 
which has been suggested to be a mechanism of  de novo 
resistance[38]. 
In summary, multiple complex and adaptive mecha-
nisms contribute to the development of  endocrine 
resistance (Figure 1). As our understanding of  the 
mechanisms that underpin resistance improves, the goal 
of  future studies is to prolong responses to endocrine 
manipulation and potentially restore endocrine sensitiv-
ity in those tumors that have become resistant, with or 
without drugs that target interconnected pathways. Based 
on this theory, we describe three different approaches to 
overcome endocrine resistance that have recently been 
explored clinically in randomized trials.
OVERCOMING ENDOCRINE RESISTANCE
Combined inhibition of the ER and RTKs
Combined inhibition with ER- and HER2-targeting 
agents: HER2 is amplified and/or overexpressed (posi-
tive) in around 15% to 20% of  human breast cancers. 
Although overexpression of  HER2 is a marker of  ag-
gressiveness and poor prognosis, HER2-positive cells are 
sensitive to anti-HER2 targeted therapy, such as trastu-
zumab[39,40]. About half  of  HER2-positive breast cancers 
co-express hormone receptors and this is associated 
with resistance to both tamoxifen and AIs, as shown in a 
number of  pre-clinical and clinical studies[25]. As a result 
of  this pre-clinical evidence, several trials have explored 
using a combination of  endocrine and HER2-targeting 
agents to overcome endocrine resistance.
Specifically, three trials have been published to date. 
The “Trastuzumab and Anastrozole Directed Against 
ER-Positive HER2-Positive Mammary Carcinoma” (Tan-
DEM) phase 3 study compared anastrozole alone with 
the combination of  anastrozole and trastuzumab as first-
line treatment for patients with HER2/HR-positive ad-
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pausal women with advanced HR-positive disease when 
treated with letrozole alone compared to a combination 
with lapatinib. Their data suggest that the population of  
patients with low quantitative expression of  ER within 
the HER2-negative population may be most likely to 
benefit from the addition of  lapatinib to letrozole, at least 
in terms of  PFS improvement. They hypothesize that 
this benefit could be related to the anti-EGFR effect of  
lapatinib.
In conclusion, these three trials suggest that the com-
bination of  an anti-HER2 agent and an AI has significant 
clinical benefit and improves PFS compared to endocrine 
therapy alone. No significant differences in overall surviv-
al (OS) were observed in any of  the trials, possibly due to 
the influence of  crossover and/or the number of  lines of  
treatment received after progression. Interestingly, these 
three trials also confirm that HER2-positive patients have 
relative endocrine resistance; in fact, women receiving 
endocrine therapy alone had response rates ranging only 
from 7% to 15% and median time-to-progression (TTP) 
ranging from 2.4 to 3.3 mo.
These three trials provide proof-of-concept that 
HER2-associated endocrine resistance may be reverted by 
targeting HER2 and that combination therapy represents 
a therapeutic opportunity for patients with these particular 
clinicopathological features.
Combined inhibition with ER- and EGFR-targeting 
agents
As previously discussed, the crosstalk between the ER 
and EGFR has been reported to be mediate endocrine 
resistance. Therefore, combination strategies have been 
evaluated in the clinic[12,46].
Although the clinical and prognostic role of  EGFR 
in breast cancer has yet to be fully characterized and is 
mainly restricted to “basal-like” tumors, a few random-
ized trials have explored the effect of  combined ER and 
EGFR targeting in women with MBCs not selected on 
the basis of  EGFR status[47].
NCT00229697 was a randomized phase Ⅱ trial that 
evaluated the addition of  the pure EGFR inhibitor gefi-
tinib to tamoxifen in patients with HR-positive advanced 
breast cancer[48]. Patients with newly metastatic disease, or 
who had recurred after adjuvant tamoxifen, during/after 
adjuvant AI, or after first-line AI, were randomized to re-
ceive tamoxifen plus placebo or tamoxifen plus gefitinib. 
A trend towards benefit from the combination therapy 
was seen in patients with tamoxifen-sensitive disease, 
with an increase in median PFS from 8.8 to 10.9 mo. In 
the AI-resistant population, no improvement in outcome 
was observed. 
Another randomized phase Ⅱ trial (NCT00077025), 
presented by Cristofanilli et al[49], evaluated the efficacy 
and tolerability of  anastrozole combined with gefitinib or 
anastrozole with placebo in tamoxifen-resistant women 
with HR-positive MBC[49]. Unfortunately, this study was 
closed prematurely due to slow accrual, but the data that 
were gathered showed that PFS was longer in patients 
receiving the combination therapy than for those patients 
receiving anastrozole plus placebo (14.7 mo vs 8.4 mo).
Both of  these studies suggest that the observed 
benefit of  EGFR inhibition can be explained by EGFR 
activation as a mechanism of  adaptation to tamoxifen in-
hibition. It would be therefore interesting to explore this 
association in an EGFR overexpressing population, like 
in the neoadjuvant study published by Polychronis et al[50]. 
In this study, both the combination of  anastrozole and 
gefitinib and, interestingly, gefitinib alone showed clinical 
activity. Although the ORR was similar in both arms, pa-
tients assigned to gefitinib and anastrozole had a greater 
decrease in tumor proliferation (as measured by Ki67 
labeling), than those assigned gefitinib and placebo.
Combined inhibition of the ER and PI3K-Akt-mTOR 
signaling
Crosstalk between the ER signaling pathway and the 
PI3K-Akt-mTOR signaling pathway is thought to play a 
crucial role in the development of  resistance to endocrine 
therapy (Figure 2). Specifically, PI3K-Akt-mTOR path-
way upregulation is associated with ligand-independent 
activation of  ER and an associated increase in expression 
of  genes regulated by ER, albeit in the presence of  anti-
estrogens[30]. Moreover, several studies have shown that 
this effect can be reverted using mTOR inhibitors, such 
as everolimus or temsirolimus[33,34]. 
These data provide a strong rationale for combining 
agents that target this pathway and anti-estrogens in an 
attempt to restore endocrine sensitivity. Based on this, we 
present a series of  clinical studies below that explore the 
efficacy of  this approach.
Everolimus
Everolimus, the 40-O-(2-hydroxyethyl) derivative of  siro-
limus (a rapamycin analogue), is an oral mTOR inhibitor 
that binds with high affinity to its intracellular recep-
tor FKBP12, a protein belonging to the immunophilin 
family. The everolimus-FKBP12 complex interacts with 
mTOR to inhibit downstream signaling[51,52].
In the phase Ⅱ trial “TAMRAD”, Bachelot et al[53] 
evaluated the efficacy and safety of  everolimus in com-
bination with tamoxifen in 111 patients with MBC who 
had relapsed after first line treatment with AIs. Fifty-
four patients were randomized to receive everolimus 
10 mg/d and tamoxifen 20 mg/d, and the remainder 
received tamoxifen alone. Patients were stratified in two 
sub-groups: those who progressed during or within six 
months after the end of  treatment with adjuvant AIs or 
progressed during the first six months of  AIs with meta-
static disease were defined having ex novo or primary re-
sistance, whereas those who relapsed six or more months 
after completion of  adjuvant AIs or after the first six 
months of  therapy with AIs with metastatic disease were 
defined having acquired resistance. 
The CBR was higher in patients treated with everoli-
mus (61% vs 42%; P = 0.045) and TTP was longer in the 
combination arm (8.6 mo vs 4.5 mo; HR 0.54; 95%CI: 
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0.36-0.81). The subgroup analysis showed that the benefit 
of  the combination therapy was greater in patients with 
acquired resistance (74% in the secondary resistance sub-
group vs 46% in the primary resistance subgroup).
Baselga et al[54] explored the activity of  this combina-
tion in the neoadjuvant setting. In a phase Ⅱ trial, 270 
postmenopausal patients with ER-positive breast cancer 
were randomized to receive letrozole 2.5 mg/d plus 
everolimus 10 mg/d or letrozole 2.5 mg/d plus placebo 
for 16 wk prior to surgery. The primary endpoint was 
clinical response. The clinical response rates were 68.1% 
vs 59.1% in the combination and placebo arms, respec-
tively (P = 0.062). Moreover, everolimus showed greater 
anti-proliferative activity (57% vs 30% in the everolimus 
and placebo arm, respectively; P < 0.01), defined as the 
reduction in cell proliferation assessed in pre- and post-
surgical biopsy specimens.  
Following these phase Ⅱ results, a larger random-
ized, double-blind, phase Ⅲ study was conducted by 
the same group[55]. The ‘BOLERO-2’ study enrolled 724 
patients with HR-positive advanced breast cancer who 
had recurred or progressed after previous therapy with a 
non-steroidal AI (letrozole or anastrozole). Patients were 
randomized to receive exemestane 25 mg/d plus everoli-
mus 10 mg/d or exemestane 25 mg/d plus placebo. The 
primary endpoint was PFS and the secondary endpoints 
were OS, ORR, CBR, safety, and quality of  life.
The trial was stopped early because the pre-planned 
interim analysis showed a better PFS in the combination 
therapy arm (6.9 mo vs 2.8 mo in the combination and ex-
emestane alone arms, respectively; P < 0.001) and a 57% 
reduction of  risk of  progression (HR = 0.43; 95%CI: 
0.35-0.54; P < 0.001). These data were confirmed in the 
final PFS analysis conducted at a median follow-up of  
18 mo[56]. PFS was 7.8 mo vs 3.2 mo (HR = 0.45; 95%CI: 
0.38-0.54; P < 0.001) in the combination and placebo 
arms, respectively, and the magnitude of  benefit was ir-
respective of  clinicopathological characteristics, including 
previous treatment. The ORRs were 12.6% vs 1.7% (P < 
0.001) in the combination and placebo arms, respectively; 
the CBR was better in the combination arm (51.3% vs 
26.4% in the everolimus and placebo arms, respectively; 
P < 0.001). The final OS results are still not available and 
are awaited with interest.
Although generally well tolerated, all the clinical stud-
ies have reported toxicity related to everolimus. Data 
from BOLERO-2 showed that a greater proportion of  
patients discontinued treatment in the everolimus arm 
than in the placebo arm (19% vs 4%, respectively) due 
to adverse events. However, no significant difference 
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Figure 2  A representation of the molecular crosstalk between estrogen receptor and the receptor tyrosine kinases and PI3K-Akt-mTOR axes. In breast can-
cer, the PI3K-Akt-mTOR pathway modulates responses to signals communicated through growth factor receptors and the estrogen receptor (ER), and this crosstalk is 
important for sensitivity to anti-endocrine therapy. In particular, Akt and ERK1/2 phosphorylate ER on key residues involved in the induction of ligand-independent acti-
vation of DNA transcription. Furthermore, the converse occurs: estradiol, bound to membrane ER, interacts with and activates a regulatory subunit of PI3K. The mam-
malian target of rapamycin (mTOR) signaling cascade is another key regulatory pathway that controls proliferation and survival in cancer cells and plays an important 
role in the molecular crosstalk with the ER pathway. Two mTOR-interacting proteins, raptor and rictor, define distinct branches of the mTOR pathway: mTOR complex 
1 (mTORC1) and mTOR complex 2 (mTORC2). Both active mTORC1 (via the phosphorylation of downstream targets, such as 4E-BP1 and p70S6 Kinase) and ac-
tive mTORC2 contribute to promoting cellular survival and proliferation. EGF: Epidermal growth factor; IGF: Insulin-like growth factor; PDGF: Platelet derived growth 
factor; PI3K: Phosphatidylinositol-3-phosphate kinase; E2: Estradiol; IRS-1: Insulin receptor substrate-1; RAS–RAF–MEK–ERK: Mitogen activated protein kinase 
pathway; HSP90: Heat shock protein 90; PDK-1: Pyruvate dehydrogenase lipoamide kinase isozyme 1; p70S6K: Protein 70S6 kinase; 4EBP1: Eukaryotic translation 
initiation factor 4E-binding protein 1; ERE: Estrogen response element.
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in overall quality of  life was reported between the two 
arms[57]. The most commonly reported toxicities related 
to everolimus were stomatitis, fatigue, rash, anorexia, and 
diarrhea; a less common but life-threating adverse event 
was non-infectious pneumonia (presenting as an acute 
deterioration in respiratory function with ground glass or 
patchy opacities on computed tomography scans), which 
was reported in about 3% of  patients. This non-infec-
tious pneumonia seemed to be immunologically mediated 
and the clinical management often required immediate 
drug interruption and high doses of  corticosteroids. 
Other concerning toxicities reported were hyperglycemia, 
hypercholesterolemia, and hypertriglyceridemia[58,59].
Temsirolimus
Temsirolimus is a compound that, similar to everolimus, 
inhibits the kinase activity of  mTOR by complexing with 
FKBP12. However, it differs from everolimus in its phar-
macokinetics and toxicity profile[60]. 
In a randomized phase Ⅱ study, Carpenter et al[61] 
explored the activity and safety of  oral temsirolimus with 
letrozole in heavily pre-treated ER-positive MBC patients. 
This trial had a three-arm design: one arm received letro-
zole alone, whereas the other two arms received letrozole 
plus temsirolimus daily (10 mg) or intermittently (30 mg), 
respectively. One-year PFS was higher in both combina-
tion arms with letrozole alone (69%, 62%, and 48%, re-
spectively). 
However, these results were not confirmed in a sub-
sequent larger randomized phase Ⅲ trial conducted by 
Chow et al[62] in heavily pre-treated MBC patients; no 
improvement in PFS was seen in the investigational arm 
and the study was stopped early. 
Temsirolimus has also been evaluated in AI-naïve 
patients. In a randomized phase Ⅲ study, 1112 post-
menopausal women with ER-positive locally advanced or 
metastatic BC with no prior exposure to AIs were ran-
domly assigned to receive letrozole plus oral temsirolimus 
30 mg/d for five days every two weeks or placebo with 
the same schedule[63]. The independent data monitoring 
committee also stopped this trial early at the second pre-
defined interim analysis because the study was deemed 
unlikely to reach its primary endpoint. The published data 
showed no difference in PFS (8.9 and 9.0 mo, respec-
tively; P = 0.25) between the groups at a median follow-
up of  9.5 mo. 
PI3K inhibitors
Alterations in the PIK3CA gene are the most common 
somatic mutations in breast cancer, and both crosstalk 
between the ER and PI3K pathways and PI3K activation 
are thought to play a role in endocrine resistance[64,65].
Specifically, PI3K pathway alterations occur in about 
70% of  breast cancers and include mutations and/or 
amplifications of  the genes encoding the PI3K catalytic 
subunits, p110α (PIK3CA) and p110β (PIK3CB), the 
PI3K regulatory subunit p85α (PIK3R1), and the PI3K 
effectors AKT1, AKT2, and PDK1. The loss of  lipid 
phosphatases, such as PTEN and INPP4B (inositol poly-
phosphate-4-phosphatase type II), can also activate the 
pathway[66-69].
In 2012, the Cancer Genome Atlas Network described 
that luminal ER+ tumors commonly harbor PI3K muta-
tions, 49% in luminal A and 32% in luminal B[70]. Fu et 
al[71] have recently shown that activation of  RTK signaling 
induces transcription of  growth-related genes and causes 
decreases in ER levels and activity, leading to an inferior 
response to endocrine therapy. Co-targeting this pathway 
with ER and PI3K inhibitors therefore appears to be a 
promising therapeutic opportunity for patients with ER+ 
breast cancer. In support of  this, Fu et al[71] found that 
the combination of  tamoxifen with a dual PI3K/mTOR 
inhibitor (BEZ-235) additively reduces cell growth in 
different ER-positive HER2-negative breast cancer cell 
line models[71,72]. Furthermore, Sanchez et al[73] suggested 
in pre-clinical testing that fulvestrant may sensitize long-
term estrogen deprived ER+ breast cancer cells to the 
therapeutic effects of  PI3K inhibitors, with an associated 
synergistic increase in apoptosis.
At the most recent San Antonio Breast Cancer Con-
ference, Juric et al[74] presented results from a phase 1b 
study of  the PI3Kα inhibitor GDC-0032 in combination 
with fulvestrant in patients with ER+ advanced breast 
cancer. GDC-0032 was administered to 17 patients at a 
range of  doses (six to nine mg/d) in combination with 
fulvestrant 500 mg every four weeks (with loading dose 
of  500 mg at day one, 14, and 28). The combination ap-
peared to be well tolerated and had promising prelimi-
nary efficacy, with a final recommended dose of  six mg 
per day. No dose limiting toxicities (DLTs) were observed 
and the main adverse events were gastrointestinal toxici-
ties (anorexia, nausea, and diarrhea), metabolic toxicity 
(hyperglycemia), and rash. Metabolic partial responses 
were observed in eight out of  11 patients (73%), includ-
ing those previously treated with fulvestrant[75].
At the same conference, another phase 1 trial report-
ed on BKM120, a novel oral pan-PI3K inhibitor, in com-
bination with fulvestrant in postmenopausal women with 
ER-positive MBC. Fulvestrant 500 mg IM was adminis-
tered monthly on day one of  each 28-d cycle (following 
the loading dose) and BKM120 was administered daily on 
day one to 28 of  each cycle. 18 patients have been treated 
at three doses of  BKM (80 and 100 mg/d continuously 
and 100 mg/d, five days on and two days off). Both 
BKM120 100 mg schedules (continuous or intermittent) 
with fulvestrant were tolerable without DLTs. Liver toxic-
ity (assessed by ALT) has been reported with BKM120, 
especially with continuous dosing, and often requires 
dose reduction but not interruption. The results of  this 
trial were promising, with over 50% clinical benefit, one 
partial response, and five prolonged disease stabilizations.
Phase Ⅲ studies of  this combination have also been 
started in the same setting and preliminary information 
was reported at the 2012 American Society of  Clinical 
Oncology (ASCO) annual meeting. For example, the 
BELLE (buparlisib breast cancer clinical evaluation) tri-
996 December 10, 2014|Volume 5|Issue 5|WJCO|www.wjgnet.com
Milani A et al . Overcoming endocrine resistance in metastatic breast cancer
als are investigating the safety and efficacy of  buparlisib 
(BKM120) with fulvestrant.
BELLE2 is a phase Ⅲ of  BKM120 plus fulvestrant in 
HR-positive HER2-negative advanced breast cancer that 
has progressed on or after AI therapy, while BELLE3 is 
a similar phase Ⅲ trial in patients with advanced breast 
cancer previously treated with AIs and refractory to en-
docrine and mTOR inhibitor combination therapy. The 
results from these trials will not be available for a few years 
(NCT01610284 and NCT01633060). BELLE4 is a phase 
II, randomized, double-blind and placebo-controlled study 
of  BKM120 in combination with paclitaxel in patients with 
HER2-negative, locally advanced or metastatic breast can-
cer, with or without PI3K pathway activation. Other com-
bination trials using different PI3K inhibitors are currently 
recruiting, for example BYL719 with letrozole or fulves-
trant, and  ongoing trials of  PI3K inhibitors combined with 
endocrine agents are summarized in Table 1. 
Multiple targeting of ER
Although the functional crosstalk between different mo-
lecular pathways and ER are thought to be the largest 
contributor to the development of  endocrine resistance, 
many other mechanisms have also been described. For 
example, cells that express mutated ER circumvent inhi-
bition by tamoxifen or long-term estrogen deprivation, 
as described above, and due to its peculiar mechanism 
of  action, fulvestrant appears to be more active in these 
situations. Fulvestrant mediates the down-modulation 
and accelerated degradation of  ER, thereby reducing its 
activity and it availability to other interacting molecules. 
Moreover, preclinical data suggest that fulvestrant retains 
and enhances its antitumor activity in the low estrogen 
environment, such as in the presence of  AIs[76]. These 
data support a strong rationale to explore the activity of  
combining fulvestrant with AIs.
To this end, three large randomized trials have as-
sessed this approach in postmenopausal women with ER-
positive MBC[77-79]. Mehta et al[79] explored the activity of  
fulvestrant (500 mg loading dose, followed by 250 mg on 
days 14 and 28 and monthly thereafter) in combination 
with anastrozole compared to anastrozole alone (1 mg/d 
in both arms) in the first-line setting in women with MBC 
previously exposed to AIs and tamoxifen in the adjuvant 
setting. Overall, the study was positive in terms of  its 
primary endpoint, with a small but statistically significant 
1.5-mo increase in median PFS. However, the combina-
tion was only beneficial in the tamoxifen-naive popula-
tion. No differences in ORR and CBR were observed in 
the two arms of  the trial.
In the second study, conducted by Bergh et al[77], wom-
en with HR-positive MBC were randomized to receive 
the same two treatments as above in the first-line setting. 
Sensitivity to AIs was defined as either no prior exposure 
or administration of  these drugs in the adjuvant setting 
and relapse occurring after one year from completion of  
adjuvant endocrine therapy. This trial failed to show dif-
ferences between the study arms in the primary endpoint 
of  TTP, or in ORR, CBR, and OS. 
In the third study, recently published by Johnston et 
al[78], patients with MBC resistant to AIs were randomized 
to fulvestrant (dose and schedule as above) plus anastro-
zole (1 mg/d), fulvestrant plus placebo or anastrozole, 
or to exemestane 25 mg/d. Patients were eligible if  they 
progressed while on AIs after a period of  at least 12 mo 
for adjuvant therapy or six months for metastatic disease. 
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Table 1  Ongoing clinical trials of PI3K inhibitors in combination with endocrine therapy in hormone receptor-positive metastatic 
breast cancer
Treatment Disease conditions Trial status Trial number
Phase Ⅰ
BYL719 + letrozole Postmenopausal women hormone receptor-positive stage Ⅳ 
breast cancer
Ongoing NCT01791478
BKM120 + fulvestrant Postmenopausal women estrogen receptor-positive stage Ⅳ 
breast cancer
Ongoing NCT01339442
BKM120 or BEZ235 + letrozole Postmenopausal women hormone receptor-positive stage Ⅳ 
breast cancer
Ongoing, not recruiting NCT01248494
XL147 or XL765 + letrozole Postmenopausal women hormone receptor-positive stage Ⅳ 
breast cancer
Completed NCT01082068
Phase Ⅱ
PF-04691502 + exemestane vs 
exemestane alone
Estrogen receptor-positive stage Ⅳ breast cancer Withdrawn prior to enrolment NCT01658176
PF-4691502 + letrozole vs letrozole 
alone
Postmenopausal women estrogen receptor-positive early (phase 
Ⅱ) and advanced (phase Ⅰb) breast cancer
Terminated NCT01430585
GDC-0941 or GDC-0980/placebo + 
fulvestrant
Postmenopausal women estrogen receptor-positive, AI treated, 
stage ⅢB-Ⅳ breast cancer
Ongoing NCT01437566
Phase Ⅲ
BKM120/placebo + fulvestrant Postmenopausal women hormone receptor-positive, AI treated, 
stage ⅢB-Ⅳ breast cancer progressed on or after mTOR inhibitor-
based treatment
Ongoing NCT01633060
BKM120/placebo + fulvestrant Postmenopausal women hormone receptor-positive, stage ⅢB-Ⅳ 
breast cancer refractory to AIs
Ongoing NCT01610284
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This study also reported no differences in terms of  PFS, 
OS, ORR, and CBR between the treatment arms.
CONCLUSIONS AND FUTURE 
PERSPECTIVES
Endocrine therapy was traditionally thought to be less ef-
fective than chemotherapy for the treatment of  women 
with MBC and was consequently demoted to a secondary 
role. Recently, our understanding of  ER biology has im-
proved and, in parallel, our therapeutic armamentarium 
has expanded with the development of  several classes of  
compounds with different mechanisms of  action. As a 
result, endocrine therapy is the confirmed leader in the 
treatment of  HR-positive MBC due to greater efficacy 
and negligible toxicity. 
However, most women treated with endocrine thera-
pies develop resistance, and several mechanisms of  resis-
tance have been described. In particular, ER appears to 
be a key player in a complex network of  signaling path-
ways that leads to proliferation and survival of  cancer 
cells. Due to the adaptability of  this network, cells can 
easily escape simple perturbations, such as those present-
ed by the currently available endocrine therapies.
Moreover, these observations have provided the 
rationale for developing drugs that target other intercon-
nected pathways. Combinations of  endocrine agents with 
or without these drugs have recently been tested in ran-
domized trials, with exciting results. 
In this paper, we have described three possible strate-
gies to overcome endocrine resistance, some of  which 
are already becoming part of  clinical practice.
Of  these, co-targeting the RTK signaling pathways 
and intracellular signaling networks is the most effective. 
Lapatinib has recently been approved in patients with 
HER2- and ER-positive breast cancer, and everolimus 
has been approved in combination with exemestane for 
women refractory to AIs. Many other drugs that target 
intracellular signaling networks, especially the PI3K-
mTOR-Akt axis, are currently under development and 
some of  these have shown promising results.
However, recent advances in the understanding of  the 
biology of  ER signaling and of  the molecular markers 
of  resistance have highlighted that ER and its pathway 
remain central to endocrine resistance. These findings are 
likely to translate into new strategies to overcome endo-
crine resistance in the near future. For example, targeting 
tumors with specific ER mutations with more potent and 
specific anti-estrogens seems to be a fascinating approach. 
All these advances have positively impacted on sur-
vival of  women with HR-positive MBC. They chart a 
course towards the biology-based selection of  treatments 
and a more rational use of  chemotherapy to improve ef-
ficacy and limit toxicity in women with breast cancer.
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